News

Civica Inc. to Expand in Greater Richmond-Petersburg Region, Investing $27.8 Million for a New Testing Facility

Nonprofit generic drug company to create 51 new jobs at testing and R&D lab in Chesterfield County that will support Petersburg manufacturing operation

RICHMOND, VA – Governor Glenn Youngkin today announced that non-profit Civica Inc. (Civica) will invest $27.8 million to establish a new laboratory testing facility at Meadowville Technology Park in Chesterfield County. The company will construct a 55,000-square-foot facility to support Civica’s Petersburg pharmaceutical manufacturing operation through quality testing and development of new products. The project will create 51 new jobs. In addition, it will host a scale-up manufacturing facility operated by Virginia Commonwealth University’s Medicines for All Institute, which will create additional employment.

“Civica’s investment is another transformational step forward in strengthening the advanced pharmaceutical manufacturing hub in the Richmond-Petersburg region and positioning Virginia as a key player in domestic drug manufacturing in America,” said Governor Glenn Youngkin. “Civica is a critical partner in the Commonwealth’s emerging pharmaceutical ecosystem that will ensure access to affordable, lifesaving medications while providing high-quality jobs and an incredible boost to our economy.”

“Civica’s new laboratory testing facility in Chesterfield County extends the footprint of the rapidly growing pharmaceutical manufacturing cluster in the region and will support the coalition’s long-term vision to serve as the world’s central access point for advanced pharmaceutical manufacturing and R&D,” said Secretary of Commerce and Trade Caren Merrick. “Today we celebrate Virginia’s vital role in addressing the shortage of affordable essential medicines in our nation and the investment in a new facility that will create high-paying jobs and accelerate research and innovation in the industry.”

“With this investment, Civica is building on its long-term commitment to patients – and to Virginia,” said Ned McCoy, Civica’s President and Chief Executive Officer. “This lab will support a skilled and highly trained workforce who will ensure Civica’s affordable insulin as well as other essential medicines meet the highest standards.”

“Chesterfield County is thrilled to have Civica’s new laboratory testing facility locate at the Meadowville Technology Park,” said Chesterfield Board of Supervisors Chairman Chris Winslow. “The new facility will play a key role in helping to support the manufacturing and testing of lower-cost generic drugs, which will help bring down costs for our residents.”

“Even prior to Civica’s announcement that they would be placing their headquarters in Petersburg, I was proud of the beneficial products they created. Today, I am ecstatic that they will be investing significantly more in Central Virginia,” said Senator Joseph D. Morrissey. “With their $27.8 million investment, Civica will be a part of Virginia’s much-needed workforce development initiatives. Thank you to Civica for providing Central Virginia, the Commonwealth, and beyond with jobs and necessary, lifesaving pharmaceuticals.”

“I want to welcome Civica to the hardworking manufacturing family in the 62nd district,” said Delegate Carrie E. Coyner. “We are thankful for your corporate commitment of bringing down the cost of medications and specifically to address the accessibility and costs of insulin. Our community is ready to provide the talent and resources for you to reach your goals.”

Civica is a nonprofit generic drug company launched in 2018 to address the problem of chronic generic drug shortages and high drug prices. In January 2021, Civica announced that it will establish a 140,000-square-foot state-of-the-art facility to manufacture sterile injectable drugs in the City of Petersburg. In addition to manufacturing essential medicines hospitals use daily, Civica recently announced plans to manufacture and distribute insulins that, once approved, will be available to people with diabetes at significantly lower prices than insulins currently on the market. Civica’s new laboratory testing facility in Chesterfield County is expected to be operational soon after the Petersburg plant reaches commercial scale in 2024.

The construction of the lab will be supported by an award from the U.S. Economic Development Administration to the Alliance for Building Better Medicine, a coalition that aims to expand essential medicines manufacturing in the Richmond-Petersburg region. Civica will provide matching capital.

The Virginia Economic Development Partnership worked with Chesterfield County to secure the project for Virginia. Governor Youngkin approved a $400,000 grant from the Commonwealth’s Opportunity Fund to assist Chesterfield County with the project.

Support for Civica’s job creation will continue to be provided through the Virginia Talent Accelerator Program, a workforce initiative created by VEDP in collaboration with the Virginia Community College System and other higher education partners, with funding support from the Governor’s administration and the Virginia General Assembly. Launched in 2019, the program accelerates new facility start-ups through the direct delivery of recruitment and training services that are fully customized to a company’s unique products, processes, equipment, standards, and culture. All program services are provided at no cost to qualified new and expanding companies as an incentive for job creation.

Brightpoint Community College has built an innovative new training program for people to gain the qualifications needed to qualify for a high-paying Manufacturing Technician role in Civica’s new Petersburg facility. Applicants interested in the program or any of Civica’s wide range of professional career opportunities can visit civicarx.org/careers.

Recent News

09/21/2022

HemoShear Therapeutics Advancing Novel Modulators Against Second Target for Horizon Therapeutics’ Gout Discovery Pipeline

HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential lead product candidates against a second target for the treatment of gout under its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP). This milestone marks the fifth payment that HemoShear has earned in accordance with the

09/21/2022

Kaléo Announces First U.S. Department of Defense Supply Contract for the Rapid Opioid Countermeasure System (ROCS) Antidote for Ultra-Potent Weaponized Opioids

Kaléo, a privately held commercial-stage U.S. pharmaceutical company, announced the execution of the first contract with the U.S. Department of Defense (DoD) for the procurement of the Rapid Opioid Countermeasure System (ROCS), a 10 mg Naloxone Auto-injector (naloxone hydrochloride injection) antidote for ultra-potent weaponized opioids. The contract includes an award for the manufacture and delivery

09/20/2022

Embody, Inc. Announces $10.4 Million Series C Funding Round

Embody, Inc., a privately-held medical device company focused on soft tissue healing, announced that it closed a $10.4 million Series C funding round led by Genesis Innovation Group’s cultivate(MD) Capital Funds LP. The financing will enable Embody to expand its world-class operations, post-market clinical studies of the recently launched Tapestry RC System for rotator cuff